Kala Bio KALA
NASDAQ KALA
$0.16 +0.01 (+3.73%)
As of: Nov 9, 2026 · 9:30 AM EST

Kala Bio (KALA) Asset Writedowns and Impairment (2025)

Updated

Analysis

Kala Bio (KALA) Asset Writedowns and Impairment (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,225.92 Bn 1,199.53 Bn 20.46 Bn
2 Johnson & Johnson 669.87 Bn 589.73 Bn 17.30 Bn
3 AbbVie 514.17 Bn 482.18 Bn 13.12 Bn
4 Merck 363.03 Bn 325.97 Bn 13.19 Bn
5 Novartis Ag 314.10 Bn 287.34 Bn -
6 Astrazeneca 290.83 Bn 264.72 Bn 13.26 Bn
7 Amgen 247.70 Bn 199.36 Bn 7.58 Bn
8 Gilead Sciences 206.67 Bn 181.78 Bn 6.73 Bn
9 Pfizer 166.55 Bn 113.91 Bn 12.56 Bn
10 Kala Bio 2.48 Mn -42.16 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 1.41 Mn
API Access

Kala Bio Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=KALA&period=max&api_key=YOUR_API_KEY